6if3: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
<StructureSection load='6if3' size='340' side='right'caption='[[6if3]], [[Resolution|resolution]] 1.50Å' scene=''> | <StructureSection load='6if3' size='340' side='right'caption='[[6if3]], [[Resolution|resolution]] 1.50Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[6if3]] is a 2 chain structure with sequence from [ | <table><tr><td colspan='2'>[[6if3]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6IF3 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6IF3 FirstGlance]. <br> | ||
</td></tr><tr id=' | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.5Å</td></tr> | ||
<tr id=' | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GTP:GUANOSINE-5-TRIPHOSPHATE'>GTP</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6if3 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6if3 OCA], [https://pdbe.org/6if3 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6if3 RCSB], [https://www.ebi.ac.uk/pdbsum/6if3 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6if3 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
[ | [https://www.uniprot.org/uniprot/ACAP2_HUMAN ACAP2_HUMAN] GTPase-activating protein (GAP) for ADP ribosylation factor 6 (ARF6).<ref>PMID:11062263</ref> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Line 19: | Line 19: | ||
</div> | </div> | ||
<div class="pdbe-citations 6if3" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 6if3" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[GTP-binding protein 3D structures|GTP-binding protein 3D structures]] | |||
*[[Ras-related protein Rab 3D structures|Ras-related protein Rab 3D structures]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: | [[Category: Homo sapiens]] | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Lin | [[Category: Lin L]] | ||
[[Category: Zhang | [[Category: Zhang R]] | ||
[[Category: Zhu | [[Category: Zhu J]] | ||
Latest revision as of 12:40, 22 November 2023
Complex structure of Rab35 and its effector ACAP2Complex structure of Rab35 and its effector ACAP2
Structural highlights
FunctionACAP2_HUMAN GTPase-activating protein (GAP) for ADP ribosylation factor 6 (ARF6).[1] Publication Abstract from PubMedRab35, a master regulator of membrane trafficking, regulates diverse cellular processes and is associated with various human diseases. Although a number of effectors have been identified, the molecular basis of Rab35-effector interactions remains unclear. Here, we provide the high-resolution crystal structures of Rab35 in complex with its two specific effectors ACAP2 and RUSC2, respectively. In the Rab35/ACAP2 complex structure, Rab35 binds to the terminal ankyrin repeat and a C-terminal extended alpha helix of ACAP2, revealing a previously uncharacterized binding mode both for Rabs and ankyrin repeats. In the Rab35/RUSC2 complex structure, Arg1015 of RUSC2 functions as a "pseudo-arginine finger" that stabilizes the GTP-bound Rab35, thus facilitating the assembly of Rab35/RUSC2 complex. The structural analysis allows us to design specific Rab35 mutants capable of eliminating Rab35/ACAP2 and Rab35/RUSC2 interactions, but not interfering with other effector bindings. The atomic structures also offer possible explanations to disease-associated mutants identified at the Rab35-effector interfaces. Rab35/ACAP2 and Rab35/RUSC2 Complex Structures Reveal Molecular Basis for Effector Recognition by Rab35 GTPase.,Lin L, Shi Y, Wang M, Wang C, Zhu J, Zhang R Structure. 2019 Mar 11. pii: S0969-2126(19)30078-4. doi:, 10.1016/j.str.2019.02.008. PMID:30905672[2] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|